
SAN FRANCISCO-A highly sensitive photon sensor has shown promise as a means of detecting early, subtle responses to neoadjuvant therapy among patients with soft tissue sarcomas, investigators from the Dana-Farber Cancer Institute reported at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).

